|
WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. |
|
|
Honoraria - Astex Pharmaceuticals; AstraZeneca; GamaMabs Pharma; GlaxoSmithKline; Lilly; Merus; MSD; Pfizer; PharmaMar; Pierre Fabre; Roche; Sanofi; SERVIER; Symphony Evolution; Takeda |
|
|
Consulting or Advisory Role - Lilly/ImClone; Novartis; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Oncology; Janssen; Roche; Sanofi |
Consulting or Advisory Role - Astellas Oncology (Inst); AstraZeneca (Inst); MSD (Inst); Roche (Inst) |
Research Funding - Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Oncology; AstraZeneca; MSD; Roche |
|
|
Employment - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Ariana Pharma |
Leadership - Ariana Pharma |
Stock and Other Ownership Interests - Ariana Pharma |
Patents, Royalties, Other Intellectual Property - Ariana Pharma (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst) |
Expert Testimony - Inivata |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
Apostolia Maria Tsimberidou |
Research Funding - Baxter (Inst); Bayer (Inst); EMD Serono (Inst); Foundation Medicine (Inst); ONYX (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Equinom |
|
|
No Relationships to Disclose |